[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635404":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":52,"collaborators":54,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":85,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Duke Kunshan University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Selective serotonin reuptake inhibitor (SSRI)","EXPERIMENTAL","Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.",[13],"Drug: Selective serotonin reuptake inhibitor (SSRI)",{"label":15,"type":16,"description":17,"interventionNames":18},"Acupuncture","ACTIVE_COMPARATOR","Manual acupuncture (not sham)",[19],"Other: Acupuncture",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","This pharmacological intervention (selective serotonin reuptake inhibitor (SSRI)) will be compared to acupuncture (for which no drugs will be involved). Treatment options for medication will be determined by the medical team, the usual care recommended for patients diagnosed with anxiety and depression. Treatment is expected to last 1 month per patient. Expected treatment plan: Administer Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.",[9],null,{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Manual acupuncture (no sham) will be compared to medication. Bilateral Baihui (GV20), Yintang (GV29), Shenmen (HT7), Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6), and Zusanli (ST36).\n\nProcedure:\n\n1. Positioning: The patient lies in a supine position.\n2. Needles: Disposable sterile acupuncture needles (specification: 0.25 mm × 40 mm, brand: Wuxi Jiajian) are used.\n3. Sterilization: Strict disinfection is performed before needle insertion.\n4. Needling Technique: After insertion, lifting-thrusting and twisting techniques are applied to achieve deqi\\* (needling sensation).\n5. Retention Time: Needles are retained for 20 minutes.\n6. Treatment Schedule:\n\n   * Sessions per week: 3 times.\n   * Course duration: 9-10 sessions per treatment course. Detailed Needling Methods for Each Acupoint Acupoint Location Needling Insertion Technique and Depth Baihui (GV20) On the head, 5 cun\\* directly above the midpoint of the anterior hairline. Horizontal insertion to a depth of 0.5-0.8 c",[15],[30],{"name":31,"affiliation":5,"role":32},"Claudia Nisa","PRINCIPAL_INVESTIGATOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":25,"email":38},"Claudia F. Nisa","CONTACT","008618151144079","claudia.nisa@duke.edu",[40],{"facility":41,"status":25,"city":42,"state":43,"zip":25,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":25},"Kunshan Mental Health Center and Kunshan Hospital of Traditional Chinese Medicine","Kunshan","Jiangsu","China","CN",{"type":47,"coordinates":48},"Point",[49,50],120.95431,31.37762,{"lat":50,"lon":49},{"type":32,"investigatorFullName":31,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Ass Prof Behavioral Science",[55,57,60],{"name":56,"class":6},"Kunshan Hospital of Traditional Chinese Medicine",{"name":58,"class":59},"Kunshan Mental Health Center","UNKNOWN",{"name":61,"class":62},"National Natural Science Foundation of China","OTHER_GOV","100635404","phase-4-comparing-acupuncture-with-medication-to-reduce-anxiety-and-depression-in-china-100635404",false,"NCT07552246","Comparing Acupuncture With Medication to Reduce Anxiety and Depression in China","Comparing Acupuncture With Medication to Reduce Anxiety and Depression in China: A Preference-based Trial Comparing Clinical Efficacy, Cost-effectiveness and Environmental Footprint","Inclusion Criteria:\n\n1. Chinese nationals 18 years old and above\n2. No mental health treatment in the past 6 months\n3. The patient diagnosis should meet one of the following ICD-10 diagnostic codes (or diagnosed as depressive state\u002Fanxiety state\u002Fanxious depression state):\n\n   1. Depressive disorder (F30-F39)\n   2. Fear anxiety disorder (F40)\n   3. Other anxiety disorders (F41)\n   4. Adjustment disorder (F43.2)\n   5. Organic\u002Fsecondary related disorders (F06)\n   6. F1x.4 Depressive disorder caused by psychoactive substances (x is a substance category, e.g., F10.4 alcohol, F11.4 opioids, etc.)\n   7. F1x.0 Anxiety disorder caused by psychoactive substances\n   8. F42.- Obsessive-compulsive disorder (often accompanied by significant anxiety)\n   9. F48.8 Neurasthenia (may be accompanied by symptoms of anxiety and depression)\n4. When using scale results (any of the following scales can be used, or other measurable scores\u002Fresults suggestive of depression\u002Fanxiety tendencies):\n\n   1. Depressive state\n\n      * Depression Self-Rating Scale (SDS) standard score ≥ 53 points, or suggesting depressive tendencies\n      * Hamilton Depression Rating Scale (HAMD-17) ≥7 points, suggesting the presence of depressive symptoms\n      * Patient Health Questionnaire-9 (PHQ-9) ≥ 5 points, suggesting the presence of depressive symptoms.\n   2. Anxiety state\n\n      * Anxiety Self-Rating Scale (SAS) standard score ≥ 50 points, or suggesting anxiety tendencies\n      * Hamilton Anxiety Scale (HAMA) ≥ 7 points, suggesting the presence of anxiety symptoms\n      * Generalized Anxiety Disorder Scale (GAD-7) ≥ 5 points, suggesting the presence of anxiety symptoms.\n\nExclusion criteria:\n\n1. Serious cardiovascular, cerebrovascular, liver, kidney and other serious life-threatening primary diseases\n2. Poorly controlled diabetes\n3. There is a risk of suicide\n4. Those with head trauma, loss of consciousness or severe mental disorders\n5. Drug, drug or alcohol abusers\n6. Received modified electrical convulsions (MECT\u002FECT), repetitive transcranial magnetic stimulation (r-TMS), vagus electrical stimulation (VNS), within half a year.\n7. Those who have received antidepressant or psychotic drugs within half a year;\n8. Those with severe skin injuries and skin diseases.\n9. Self-injury or even suicidal behavior occurs during the research process;\n10. Other diseases that suddenly become unsuitable for continued participation in the study during the study;\n11. Other conditions that the supervising physician deems unsuitable for continued participation in the study.","ALL","18 Years",{"count":73,"type":74},120,"ESTIMATED","INTERVENTIONAL",[77],"PHASE4","The main objective of this study is to compare medication (usual care) with acupuncture (as a standalone comparator) to identify the most (cost)effective and environmentally sustainable intervention to reduce anxiety and mild to moderate depression in adults in China.",[80],"Anxiety Depression",[82,15,83,84],"Depression","Antidepressants","anxiety","NOT_YET_RECRUITING","2026-04-20",{"date":88,"type":89},"2026-04-27","ACTUAL",{"date":91,"type":74},"2026-04-01",{"date":93,"type":74},"2027-12-31",{"name":5,"class":6},1]